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Abstract: Several epidemiological studies have investigated the association between the dietary
flavonoid intake and gastric cancer (GC) risk; however, the results remain inconclusive. Investigating
the relationship between the different classes of flavonoids and the histological types and origin of
GC can be of interest to the research community. We used data from a population-based multi-case
control study (MCC-Spain) obtained from 12 different regions of Spain. 2700 controls and 329 GC
cases were included in this study. Odds ratios (ORs) were calculated using the mixed effects logistic
regression considering quartiles of flavonoid intakes and log2. Flavonoid intake was associated
with a lower GC risk (ORlog2 = 0.76; 95% CI = 0.65–0.89; ORq4vsq1 = 0.60; 95%CI = 0.40–0.89;
ptrend = 0.007). Inverse and statistically significant associations were observed with anthocyanidins,
chalcones, dihydroflavonols and flavan-3-ols. The isoflavanoid intake was positively associated with
higher cancer risk, but without reaching a statistical significance. In general, no differences were
observed in the GC risk according to the location and histological type. The flavonoid intake seems
to be a protective factor against GC within the MCC-study. This effect may vary depending on the
flavonoid class but not by the histological type and location of the tumor. Broader studies with larger
sample size and greater geographical variability are necessary.
Keywords: flavonoids; intake; gastric cancer; case-control study; MCC-Spain
1. Introduction
Gastric cancer (GC) is one of the most relevant malignancies. It is the fifth most common cancer
and the third in the mortality ranking world [1,2]. In many countries, a survival of five years after
diagnosis is under 30% [3]. Incidence rates show a great geographical variability, probably caused
by dietary patterns, genetic differences and exposure to carcinogens (e.g., Helicobacter pylori infection,
smoking or processed meats) [1].
The intake of fruits and vegetables has been shown to be inversely related to cancer risk [4–6]
and a high intake of fruits and vegetables is recommended for cancer prevention [7]. One of these
beneficial effects has been partially attributed to the high flavonoids content of these foods [8]. In the
case of GC, these evidences are limited.
Flavonoids are secondary metabolites present in a wide variety of plants, involved in
photosynthesis, and in the defense against both pathogens and ultraviolet radiation. The flavonoids
cannot be produced by the human body, so they must be ingested by eating different plant-based
foods (such as fruits and vegetables). These compounds have been shown to present preventive
properties for a wide variety of diseases, such as cancer, cardiovascular diseases [9] or osteoporosis [10].
Accordingly, flavonoids consumption could reduce the risk of cancer development through various
mechanisms [11–13], such as protection against DNA damage [14], blocking specific carcinogen
pathways [15], inducing apoptosis [16], modulating cellular proliferation, antioxidant properties,
anti-inflammatory [17], inhibiting angiogenesis [18], and suppressing matrix metalloproteinases
secretion and tumor invasive behavior [19]. In addition, some flavonoids have antimicrobial effects,
inhibiting the growth of H. pylori [20,21].
Although several studies have evaluated the inverse relation between the flavonoid intake and
the digestive tract cancer risk [8,22–25], the epidemiological evidence is still insufficient [8]. A recent
meta-analysis concluded that dietary flavonoids could reduce the risk of GC in the European population
but not in the US or Asia [23]. This difference between the studies in Asia, America and Europe,
suggest that the heterogeneity between the results could be partially explained by the geographical
variability of food consumption.
One of the possible causes of the lack of consistency in the results between populations could be
the several flavonoid subclasses by GC subtype. There are differences among GC risk factors by the
anatomical and histological subtype [26,27]. According to their chemical structure, flavonoids can be
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classified into six principal subclasses: Flavonols, flavones, flavanones, flavan-3-ols, anthocyanins and
isoflavones [17,28].
We hypothesize that the intake of flavonoids is associated with different effects on gastric cancer
according to the subclass of the flavonoid intake analyzed and the histological type or location of
gastric cancer.
2. Materials and Methods
2.1. Study Population
The MCC-Spain is a large population-based multi-case control study evaluating environmental
exposures and genetic factors of common tumors in Spain [29]. Clinical and epidemiological data from
cases of histologically confirmed gastric tumors were collected from 2008 to 2013 in public hospitals.
The subjects were previously informed about the study, and those who volunteered signed an informed
consent for their participation. In the present study, we included 329 cases of GC and 2700 matched
controls, Figure 1. The MCC-Spain study has been approved by the ethics committee of each area,
and it also follows the Declaration of Helsinki and the Spanish Data Protection Act 1999 [30].
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Figure 1. Algorithm for selection of controls and cases.
The inclusion criteria for cases were the following: Living for at least six months in the same area,
and being 20–85 years old. Controls were selected randomly from lists of the primary care area from
cases and they were matched by the age and area.
2.2. Variables and Data Collection
Cases and controls were interviewed by trained personnel, to collect information on
sociodemographic factors, health behaviors (such as type, frequency and duration of physical activity,
or smoking), medical conditions, previous treatments received, and personal and family history of
cancer. In addition, a validated food frequency questionnaire (FFQ) [31] to collect dietary habits and
past alcohol consumption (from 30 to 40 years old) was used. Data regarding the histological subtype
(intestinal and diffuse) and anatomical location of the gastric tumors (cardia and non-cardia) were
collected by qualified personnel.
2.3. Ethics Approval and Consent to Participate
The protocol of the MCC-Spain study was approved by the ethics committees of the participating
centres. All participants were informed about the study objectives and signed an informed consent
Nutrients 2019, 11, 967 4 of 15
form. Confidentiality of the data was secured by removing personal identifiers in the datasets,
(Ley orgánica 3/2018, de 5 de diciembre de Protección de datos personales y garantía de los derechos
digitales). The database was registered in the Spanish Agency for Data Protection, number 2102672171.
Permission to use the study database will be granted to researchers outside the study group,
after revision and approval of each request by the Steering Committee. More details on the organization
of the project can be found online at http://www.mccspain.org. More detailed information can be found
in a previous article published by the MCC-Spain project research group [29]. The MCC-Spain study
has been approved by the ethics committee of each area, and it also follows the Declaration of Helsinki.
2.4. Assessment of Flavonoid Intake
The validated MCC-Spain FFQ [31,32] included questions about the frequency of consumption of
foods grouped under ten food categories with 140 item questionnaire: (1) Meat products (including
items of poultry and eggs, pork, beef, lamb, fish and seafood, and precooked meat-derived food),
(2) vegetables and legumes, (3) fruits and nuts, (4) dairy products, (5) cereals (including bread and
pasta), (6) sauces and seasonings, (7) oils and fats, (8) sweets and snacks, (9) vitamins and mineral
supplements, (10) alcoholic and other beverages.
The amount of each food consumed daily was estimated based on reference tables of servings
of food. Similarly to other studies, if a given food was a mixture of several others (e.g., “gazpacho”
or vegetable puree) the recipe was calculated, i.e., the contribution of each ingredient to the total
content [33]. Total energy intake, as well as the consumption of the each food as mentioned above
were also estimated. Moreover, some questions about general dietary habits were included in the
questionnaire and were used to adjust the responses to the FFQ following the methodology described
in Calvert et al. [34]
2.5. Analysis of Flavonoid Intake
The flavonoid subclasses considered in the present study (hereinafter referred to as ‘flavonoids’ if
not otherwise stated) were anthocyanidins, chalcones, dihydrochalcones, dihydroflavonols, flavan-3-ols
(also called flavanol monomers), flavanones, flavones, flavonols, isoflavonoids, and proanthocyanidins
(also called flavanol oligomers and polymers).
A subset of 58 foods from the MCC-Spain FFQ were considered for analysis of the flavonoids
intake, including vegetables and legumes, fruits, cereals, sweets and snacks, and alcoholic and
other beverages. The dietary intake of flavonoids, expressed as aglycones, was estimated using
the Phenol-Explorer database [35], except for proanthocyanidins, which were estimated using the
most recent US Department of Agriculture (USDA) database on proanthocyanidins [36]. We have
used aglycone equivalents for the flavonoid intake estimation, instead of considering the amount
of all individual chemical flavonoid species (glucosides, glucuronides, etc.) reported in the food.
The rationale behind this decision was to standardize data from the results of different analytical
methods to facilitate cross-study comparisons [37].
Briefly, the process used to estimate the flavonoid contents involved looking for concordance
among the food subset used and the foods included in the Phenol-Explorer database, and obtaining
the aglycone equivalents for each flavonoid subclass and food. The flavonoid intake was calculated
in milligrams per day, using the food consumption data from the FFQ and the aglycone flavonoid
content of each food referred in the Phenol-Explorer database. No retention factors were applied
in the calculation of the amount of flavonoids ingested. The data from Phenol-Explorer contain
information on the flavonoid concentration obtained from both chromatography and chromatography
after hydrolysis analytic methods.
Chromatography is the most used technique to estimate the concentration of polyphenols in
foods, and their results are expressed as glycosides, which can be expressed in aglycones with a simple
calculation. On the other hand, we find chromatography after hydrolysis, a less used method that
expresses the result in aglycones [38].
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The number of foods with flavonoid content obtained by the chromatography method is higher
than chromatography after hydrolysis, but even so there are some foods or flavonoid classes of which
we only have information by chromatography after hydrolysis. In order not lose information from them,
we complete it with chromatography after hydrolysis when there is no information of chromatography.
To avoid having the content of flavonoids expressed in two different units (glycoside and aglycone)
we have transformed the glycoside values obtained from chromatography to aglycone, through the
following equation (Ec.1). Given that the chromatography method does not provide information on
the flavonoid content for all foods, this information was completed with data from chromatography
after hydrolysis.
P aglycone mg
100mg
=
(
[glucoside]
Pm glucoside
)
× Pm aglycone (Ec.1) (1)
Flavonoid intakes were adjusted for the total energy intake [39] to obtain a measure concerning
the isocaloric intake of flavonoids. The residues were added to the flavonoid consumption preset for
an energy intake corresponding to the average intake between the control subjects stratified by gender.
Intakes concerning flavonoid quartiles were established according to the distribution among
controls stratified by gender, and the lowest category of consumption was used as a reference.
2.6. Statistical Analysis
Descriptive statistics of the characteristics of the participants were obtained for controls and cases
by both the tumor specific location and histology. The consumption of flavonoids were log2-transformed
as data was right-skewed [40]. On the other hand, its interpretation is simpler, given that the odds ratio
(OR) indicates the risk of GC when duplicating the intake. The flavonoid intake was analyzed both as
categorical (grouping the intake of flavonoids into quartiles of their distribution among controls) and
continuous (transformed to log2).
ORs of GC and the corresponding 95% CI were adjusted using multivariate mixed logistic
regression models to assess the association between the flavonoid intake and risk of cancer, including
the study area as a random effect term. Other variables included in the model were age, socioeconomic
status, alcohol consumption, smoking status, salt intake, body mass index (BMI), physical activity
as metabolic equivalent task (MET), first-degree family history, red meat intake, vegetables intake,
and total energy intake. The stata statistical software release 13 [41] was used for the mixed effects
logistic regression, as well as the Python version 3.14 [42] and R version 3.6 [43] for the extraction of
Phenol-Explorer web data on the polyphenol content in foods, and for the calculation of the flavonoid
consumption by the individuals, respectively.
3. Results
The current study includes 329 GC cases and 2700 controls. The characteristics of cases and
controls are shown in Table 1. The proportion of cases with the first-degree family history of GC (16.1%)
was higher than controls (6.3%). Cases were more likely to have a higher intake of alcohol and salt. The
daily amount of flavonoids ingested by all subjects is presented in Table 2, and no significant differences
between controls and cases were found. We found a similar proportion of flavonoid-containing foods
consumed in both controls and cases, with the lower overall intake of each flavonoid subclass in cases.
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Table 1. Characteristics of the study subjects.
Variables
Controls (%)
Cases (%)
Total By Anatomical Subtypes By Histological Subtypes
(n = 2 700) (n = 329) Cardia (n = 84) Non-Cardia (n = 238) Intestinal (n = 122) Diffuse (n = 75)
Age mean ± SD 63.53 ± 0.21 65.40 ± 0.68 63.37 ± 1.26 66.06 ± 0.82 69.49 ± 0.96 61.79 (1.56)
Gender (men, %) 56.2 72.6 91.6 65.5 70.4 60.0
Socioeconomic status
High (%) 448 (16.59) 27 (8.21) 9 (10.71) 18 (7.56) 8 (6.56) 8 (10,67)
Medium (%) 1 361 (50.41) 146 (44.38) 38 (45.24) 103 (43.28) 49 (40.16) 34 (45.33)
Low (%) 891 (33.00) 156 (47.42) 37 (44.05) 117(49.16) 65 (53.28) 33 (44.00)
Smoking status (%)
yes 1 531 (56.70) 201 (61.09) 65 (77.38) 130 (54.62) 60 (49.18) 45 (60.00)
no 1 169 (43.30) 128 (38.91) 19 (22.62) 108 (45.38) 62 (50.82) 30 (40.00)
GC family history (%)
yes 170 (6.30) 53 (16.11) 11 (13.0) 40 (16.81) 27 (22.13) 13 (17.33)
no 2 530 (93.70) 276 (83.89) 73 (86.90) 198 (83.19) 95 (77.87) 62 (82.67)
Physical activity (METS*h/week)
<8 1 374 (50.89) 201 (61.09) 50 (59.52) 147 (61.76) 66 (54.10) 48 (64.00)
≥8 1 326 (49.11) 128 (38.91) 34 (40.48) 91 (38.24) 56 (45.90) 27 (36.00)
Body mass index (kg/m2)
≤25 1 026 (38.00) 103 (31.31) 21 (25) 80 (33.61) 41 (33.61) 32 (42.67)
>25–30 1 129 (41.81) 150 (45.59) 37 (44.05) 110 (46.22) 59 (48.36) 31 (41.33)
≥30 545 (20.19) 76 (23.10) 26 (30.95) 48 (20.17) 22 (18.03) 12 (16.00)
Alcohol consumption (g/day)
0 418 (15.48) 47 (14.29) 8 (9.52) 39 (16.39) 22 (18.03) 13 (17.33)
<12 1 179 (43.67) 103 (31.31) 16 (19.05) 84 (35.29) 40 (32.79) 27 (36.00)
12–47 787 (29.15) 101 (30.70) 34 (40.48) 66 (27.73) 30 (24.59) 22 (29.33)
>47 316 (11.70) 78 (23.71) 26 (30.95) 49 (20.59) 30 (24.59) 13 (17.33)
Vegetables total intake (g/day), mean ± SD 191.32 ± 2.42 180.80 ± 6.95 184.76 ± 18.32 177.88 ± 7.04 189.25 ± 9.7 185.63 ± 13.87
Red meat intake (g/day), mean ± SD 64.02 (0.76) 84.35 (2.94) 97.50 (6.54) 80.10 (3.28) 84.63 (4.58) 73.12 (5.19)
Sodium intake (mg/day), mean ± SD 3 008.64 (24.04) 3 529.30 (86.26) 3 758.56 (200.71) 3443.85 (94.85) 3 403.23 (144.63) 3 821.43 (187.65)
Total flavonoid intake (mg/day), mean ± SD 371.25 (3.72) 358.48 (9.88) 371.15 (18.63) 351.18 (11.69) 367.16 (14.72) 362.48 (24.51)
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Table 2. Average flavonoid consumption (mg/day) and percentage of total flavonoid subclass daily intake in all subjects of the study sorted by the three most
consumed foods.
Flavonoids Subclass Flavonoid Intake mg/day ± SD
Most Consumed Foods by Flavonoid Subclass Content-Gastric Cancer-All Controls
First (%) Second (%) Third (%)
Anthocyanins 22.3 ± 0.35 Wine [Red] 31.3 Sweet cherry 24.7 Strawberry 15.9
Chalcones 0.004 ± 0.0001 Beer [Regular] 98.2 Beer [Alcohol free] 1.8 - -
Dihydrochalcones 1.15 ± 0.023 Apple 95.3 Non-orange pure juice 5.5 - -
Dihydroflavonols 1.87 ± 0.06 Wine [Red] 97.8 Wine [Rosé/White] 2.2 - -
Flavan-3-ols 26.94 ± 0.33 Apple 33.4 Wine [Red] 20.55 Broad bean seed 13.64
Flavanones 43.81 ± 0.69 Orange/Tangerine 75.1 Orange pure juice 21.1 Tomato 1.48
Flavones 3.88 ± 0.08 Globe artichoke 24.7 Orange pure juice 18.0 Olives 16.16
Flavonols 23.75 ± 0.28 Swiss chard 34.2 Lentils/Chickpea/Commonbean 15.9 Wine [Red] 10.7
Isoflavonoids 1.35 ± 0.11 Soy milk 95.3 Lentils 4.3 Nuts 0.27
Proanthocyanidins 200.99 ± 2.16 Beans 32.5 Apple 23.3 Wine [Red] 11.1
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The results presented in Figure 2 are indicative of a statistically significant dose-dependent inverse
association of flavonoids intake and GC risk (ORlog2 = 0.76; 95%CI = 0.65–0.89. ORq4vq1 = 0.60;
95%CI = 0.40–0.89; ptrend = 0.007). A statistically significant inverse association was observed with
the intake of anthocyanidins (ORlog2 = 088; 95%CI = 0.80–0.96. ORq4vq1 = 0.68; 95%CI = 0.46–1.01;
ptrend = 0.019); chalcones (ORlog2= 0.89; 95%CI = 0.83–0.95. ORq4vq1 = 0.54; 95%CI = 0.36–0.81;
ptrend = 0.001); dihydroflavonols (ORlog2 = 0.89; 95%CI = 0.84–0.95. ORq4vq1 = 0.50; 95%CI = 0.34–0.75;
ptrend = 0.001) and flavan-3-ols (ORlog2 = 0.82; 95%CI = 0.73–0.92. ORq4vq1 = 0.56; 95%CI = 0.36–0.88;
ptrend = 0.01). An inverse association was also observed with the intake of proanthocyanidins
although the effect was only statistically significant when using the log2 transformation of the
flavonoid intake (ORlog2 = 0.82; 95%CI = 0.71–0.94) but not in the Q4 compared to Q1 analysis
(ORq4vq1 = 0.91; 95%CI = 0.59–1.39; ptrend = 0.821). Dihydrochalcones intake was statistically significant
positively associated with GC risk when was evaluated in quartiles, but not as a log2 (ORlog2 = 1.02;
95%CI = 0.95–1.11. ORq4vq1 = 1.52; 95%CI = 1.02–2.28; ptrend = 0.02).Nutrients 2019, 11, x FOR PEER REVIEW 7 of 14 
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Adjusted ORs and 95% confidence intervals (CI) of GC according to the flavonoid intake. ORs
were adjusted for age, gender, socioeconomic status, area of residence, GC family history, body mass
index, smoking, physical activity, energy, sodium, red meat, vegetables and past alcohol intake.
No statistically significant differences have been observed in the behavior of the total intake of
flavonoids and their respective subclasses for the different GC locations or histological subtypes (see
Tables S1 and S2). Likewise, no statistically significant differences were observed in the behavior of the
total intake of flavonoids and their respective subclasses for men and women separately but it has
been observed that the differences are statistically significant only in men (see Tables S3 and S4).
4. Discussion
Several reviews have been published summarizing the epidemiological evidence on the inverse
association between the dietary polyphenol intake and cancer risk, suggesting many biological
benefits [24,44,45]. These benefits of flavonoids consumption could be related to lower GC risk through
various mechanisms such as the antioxidant effect, blocking carcinogen pathways, inducing apoptosis,
and inhibiting the growth of H. pylori [20,21]. Even low amounts of polyphenols can be continually
absorbed and significantly increase the concentrations both at the plasma and cellular level [46].
Further, it has been observed that some classes of flavonoid can have an effect on cells even in µmolar
concentrations and can interact on many molecular targets [47].
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A case-control study conducted in Italy [25] mentions that the protective effect of fruit and
vegetables on GC risk were attributable to a high consumption of flavonoids.
Our results suggest that the intake of total flavonoids could act as a protective factor in the
development of GC, reducing the risk between 24% (log2) and 40% (Q4vsQ1). A meta-analysis on the
flavonoid intake and GC has shown clear protective effects from the total intake of flavonoid [23] for the
European population. Among the studies included, two of them found a significant protective effect of
the flavonoid intake on all GC cases, regardless of histological type and location [22,48], by reducing
the risk 19% (log2) in the Zamora-Ros’ study [22] and 51% (Q3vsQ1) in the Woo’ study [48].
In the analysis of the effect of the flavonoid intake by subclasses we have observed three different
behaviors: Protective effect, null effect, and risk effect. Flavonoid subclasses with the protective effect
include chalcones, dihydroflavonols, proanthocyanidins, anthocyanins, flavan-3-ols, flavanones.
This is the first study analyzing the effect of chalcones and dihydroflavonols on all cases of GC.
A compound of chalcones, xanthumol, induced the cell death by the apoptosis and S phase cell cycle
arrest [49,50], which could explain the protective effect of chalcones. But nowadays, there are no studies
analyzing the effect of dihydroflavonols on GC in vivo, in vitro or in epidemiological trials. In the case
of proanthocyanidins, we found a protective effect like in the Rossi et al. study [25]. An in vitro study
indicated that proanthocyanidins are strong antioxidants with low cytotoxicity, which could play a
relevant role in inducing the cancer cell apoptosis and cell cycle arrest [51].
Regarding the anthocyanins, a protective trend was reported in the study carried out by
Woo et al. [48]. Among anthocyanins, delphinidin has been shown to have strong anticancer activities,
possibly due to the suppression of the NF-κB pathway [52,53]. A study found that delphinidin
significantly suppressed invasion and metastasis of lung cancer cells by downregulating the matrix
metalloproteinase [54].
In the Woo et al. study, the flavonoid subclass flavan-3-ols showed a protective effect in all cases of
GC, similar to the one described in our results. Flavan-3-ols have the most complex structures among
subclasses of flavonoids. It has been found that several GC cell lines were sensitive to epicatechingallate
(EGCG), a well-studied flavan-3-ol, by inducing apoptosis due to the inhibition of an anti-apoptotic
protein [55]. Many signaling pathways might be affected by the EGCG treatment and it has been
shown that EGCG exerts anti-proliferative effects in the GC cell by preventing the b-catenin oncogenic
signaling pathway [56].
The results on flavanones obtained by Woo et al., agree with the results obtained in our study,
indicating a protective effect of this subclass for all cases of GC. Concerningthe flavanones class,
a statistically significant effect was found in the GC cells with naringenin, by inhibiting the cancer cell
proliferation and migration, and inducing apoptosis, which might be related to its inhibition of the Akt
signaling pathway [57]. Another study in colon cancer cells suggested that the pro-apoptotic activity
of naringenin was mediated by the p38-dependent pathway [58]. Zhang et al., indicated that another
treatment with flavanone, hesperetin, decreased cell proliferation and induced apoptosis through
promoting the intracellular ROS accumulation [59].
On the other hand, our study shows that the flavonoid subclass called flavones seems to have no
effect on GC. These results are not in line with other published articles such as Woo et al., whose study
found a protective effect of this subclass; or Chen et al., whose study observed apoptotic effects of
flavones in human GC cells in their in vitro. Referring to flavones, only one in vitro study has observed
apoptotic effects in GC [60].
However, isoflavonoids and dihydrochalcones, were associated with an increased risk of GC.
A study about the effect of the isoflavonoid intake and GC risk in Japan observed that this flavonoid
subclass was not a significant risk factor of the GC risk in either men or woman [61]. On the contrary,
in the Takayama study [62], their results show a non-significant effect of the isoflavonoid intake and
GC risk in men, but showed statistically significant protective effects in women. The present study
had a limited number of women diagnosed with GC, which did not allow us to draw conclusions.
Furthermore, the differences in isoflavonoid intakes are outstanding: 1.4 mg/day in our study and
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72.6 mg/day in the Japanese study. The results of the present study reveal an increased GC risk with
increased dihydrochalcones intake, but no previous studies have evaluated this association. Therefore,
results have to be interpreted with caution.
We did not find relevant differences in the effect on the different histological subtypes or localization
of GC according to the intake of the different subclasses of flavonoids. Although the subtypes of
GC have different risk factors [26], they share the probable protective effect of the intake of fruits
and vegetables [27], which may explain our results. Nevertheless, the effect of flavonoids as a
chemopreventive agent (that inhibits tumor promotion by inducing cell cycle arrest and by promoting
apoptotic cell death) could protect all GC subtypes. The analyses carried out by the CUP [1] taking into
account 24 studies on the consumption of fruits and vegetables in relation to the risk of developing GC
indicate that a high consumption decreases the risk, without observing differences in the protection
between anatomical subtypes. These results may be related to the protective effects of flavonoids,
present in fruits and vegetables [1].
Contrary to our results, a Swiss study of the flavonol compound (quercetin) indicates a statistically
significant protective effect in all GC and GC subtypes [63]. This difference in the results could be
explained by the use of a different number of flavonols. In the present study we included all compounds
of flavonols, whereas Ekstrom’s et al. study only included quercetin [63]. The EPIC study [22], reports
the isoflavonoid intake similar to our data, suggesting a risk trend between the intestinal GC subtype
for isoflavonoid. The lack of studies that analyze all cases, all flavonoid classes by location and
histological subtype make the comparison difficult.
The evaluation of the effects of the flavonoids intake and cancer risk may be hindered by a
number of underlying factors, including the difficulty to assess the bioavailability of flavonoids,
differences in the estimation of their content in foods between database sources (USDA compared to
Phenol-Explorer), the use of retention factors to take into account the cooking losses or the accuracy
of FFQs. All these effects contribute to limit the accuracy of epidemiological studies. Furthermore,
flavonoids are extensively metabolized within the human body after ingestion, both at the hepatic
and colonic level, after interaction with the gut [64,65], which varies widely among individuals and
could affect the response of the flavonoid consumption. We must take into account that a part of the
variability between the results from different studies could be attributable to the heterogeneity of the
dietary pattern of each country, since the flavonoid content in food can vary according to the different
plants species, and environmental, geographic and storage conditions [64].
Regarding the tests of the effect of flavonoids in vivo and in vitro, these also have their limitations,
and we only resort to these types of studies when we do not find epidemiological studies to discuss
results. In vitro studies there are also numerous factors that are not contemplated, such as the effects
of the microbiota on the “restructuring of polyphenols”, as well as their interaction on the ABC type
transporters [66], the synergistic or antagonistic effects between the classes of flavonoids, since not only
one class of flavonoid is consumed at the same time and, the interpersonal variation of the bioavailability
of the flavonoids [67]. For these reasons, the results of in vivo, in vitro and epidemiological studies
should be moderate in their conclusions since they all have their limitations, and explain the different
results between studies.
The main sources of some flavonoids subclasses, such as chalcones, dihydrochalcones and
dihydroflavonoids come from alcoholic beverages (wine and beer). According to some reports, reactive
metabolites of alcohol are carcinogenic to humans [68]. This increased risk could be also explained
by the production of prostaglandins, generation of oxygen radical species and lipid peroxidation.
In addition, alcohol interferes with retinoid metabolism which could affect cellular growth, cellular
differentiation and apoptosis. The WCRF/CUP found a statistically significant risk effect of 45 grams of
alcohol consumed per day [1]. In our database, near 85% of individuals are below this value. Since the
present study is based on a case-control study design, it is possible that the cases are applied as a
lower consumption of alcohol than the real one, as a consequence these flavonoids appear as protective
facts [69].
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There are differences in the incidence of GC by gender, probably due to hormonal factors and life
styles [26]. Even though no statistically significant differences were observed in the behavior of the total
intake of flavonoids and their subclasses for men and women separately, we only found statistically
significant results for men, probably due to the small number of female cancer cases included within
this study.
Our study shares certain limitations known to other epidemiological studies related to the accuracy
of the data inferred from indirect food intake reporting methods such as FFQs. Moreover, the aglycone
flavonoids content in food was estimated without considering the retention factors, which could
explain the losses during cooking. However, this information is not available for most of the individual
flavonoids and further research is needed to fill the gaps within the databases.
On the contrary, this is the first study reporting the effect of dihydrochalcones and dihydroflavonols
subclasses on GC stratifying by the anatomic and histological GC subtypes for men and women.
The inclusion of the vegetable intake in the final-adjusted model could have also decreased the potential
to find significant protective effects of flavonoids. Our models are over-adjusted by the energy intake,
resulting in more restrictive outcomes, making it sometimes difficult to obtain significant associations
between the flavonoid intake and GC. A complete database has been automatically generated including
all available information on the flavonoid content in Phenol-Explorer, together with the mixing of
data extracted from chromatography and chromatography after hydrolysis, the food ponderations of
FFQ, and the high number of case and control records with all variables related with GC, resulting
in an increased accuracy from the viewpoint of nutritional epidemiology. In addition, in this study,
the information has been obtained in a similar way for cases and controls. We used a comprehensive
methodology to evaluate the flavonoids intake, obtaining similar results to other case-control studies.
Overall, our data on the total intake of flavonoid in the Spanish population sampled by the MCC-Spain
study is consistent with previous reports [70].
Our results are in accordance with the recommendations made by CUP, which suggest that a low
intake of fruit increases the risk of stomach cancer [1]. In this sense, one of the possible strategies to
follow to reduce the risk of gastric cancer, and according to our results, is an increase in the consumption
of fruits and vegetables rich in flavonoids.
5. Conclusions
As conclusion, results of this study suggest that the intake of flavonoids could influence the
development of GC by lowering the risk, independently of the anatomic and histological subtypes of
GC. We observed an inverse association between the flavonoid intake and risk of GC in men, but not
in women, probably due to the insufficient sample size.
Further studies related to this research should consider a larger sample size, which could help
identify more clearly the preventive role of the flavonoid intake on GC and elucidate the mechanisms
underlying its etiology.
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